Tango Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference
Tango Therapeutics (NASDAQ:TNGX) announced its upcoming participation in the 2025 Cantor Global Healthcare Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Tango Therapeutics (NASDAQ:TNGX) announced its upcoming participation in the 2025 Cantor Global Healthcare Conference. The company's President and CEO, Barbara Weber, M.D., will participate in a fireside chat on September 3, 2025, from 2:45-3:15 PM ET.
Investors can access the live webcast through the "Events & Presentations" section on the company's investor relations website. The presentation recording will remain available for 90 days following the event.
Details
News Market Reaction – TNGX
On Aug 26, the day this news came out, TNGX closed 0.60% below the previous close.
Data tracked by StockTitan Argus for the Aug 26 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in a fireside chat at the 2025 Cantor Global Healthcare Conference on Wednesday, September 3 at 2:45-3:15 PM ET.
The live webcast will be available under the "Events & Presentations" tab on the “Investors” page of the Company's website on the day of the event. A replay of the webcast will be archived on the Company's website for 90 days following the presentation.
About Tango Therapeutics
Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. For more information, please visit www.tangotx.com.
Investors and Media:
Elizabeth Hickin
IR@tangotx.com
media@tangotx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.